Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetically Downregulated Breast Cancer Gene 2 through Acetyltransferase Lysine Acetyltransferase 2B Increases the Sensitivity of Colorectal Cancer to Olaparib

25 Nov 2023

Abstract excerpt

Olaparib suppresses DNA damage repair by inhibiting the poly ADP ribose polymerase (PARP), especially in cancers with BRCA1/2 mutations or the BRCA-ness phenotype. However, the first trials showed that some patients with defective DNA damage repair are still resistant to olaparib. The recovery of the wildtype BRCA is a prominent mechanism of PARP inhibitor (PARPi) resistance in BRCA-deficient tumors, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38067284
DOI: 10.3390/cancers15235580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetically Downregulated Breast Cancer Gene 2 through Acetyltransferase Lysine Acetyltransferase 2B Increases the Sensitivity of Colorectal Cancer to OlaparibPMID 38067284Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion MutationsSemantic proximity Read ↗

Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: TalazoparibSemantic proximity Read ↗

A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.Semantic proximity Read ↗

ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2−/− Ovarian Cancer CellsSemantic proximity Read ↗

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerSemantic proximity Read ↗

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity Read ↗

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitorSemantic proximity Read ↗

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancerSemantic proximity Read ↗

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, TalazoparibSemantic proximity Read ↗

The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.